November 14, 2012

Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update

SOUTH EASTON, Mass., Nov. 14, 2012 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2012 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone or through a live web-cast. The teleconference and web-cast information is provided below:

Date: Thursday, November 15, 2012
Time: 4:15 p.m. Eastern Standard Time (EST)

To attend this teleconference via web-cast, please go to the Company's website: www.pressurebiosciences.com

To attend this teleconference via telephone:
Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 (Canada); (302) 607-2001 (Int'l)

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call and will be accessible through the Company's website.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following link: http://www.pressurebiosciences.com

Investor Contacts:
Richard T. Schumacher, President & CEO
Joseph Damasio, Jr., V.P. of Finance and Adm.
Pressure BioSciences, Inc.
(T) 508-230-1828

SOURCE Pressure BioSciences, Inc.